Paper39157201
TLR2 Derangements Likely Play a Significant Role in the Inflammatory Response and Thrombosis in Patients with Ph(-) Classical Myeloproliferative Neoplasm.
Wang JC and 10 others. Mediators Inflamm, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. TLR2 Derangements Likely Play a Significant Role in the Inflammatory Response and Thrombosis in Patients with Ph(-) Classical Myeloproliferative Neoplasm. Papers, record 39157201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39157201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TLR2 Derangements Likely Play a Significant Role in the Inflammatory Response and Thrombosis in Patients with Ph(-) Classical Myeloproliferative Neoplasm.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Toll-Like Receptor 2 | Major topic |
| Myeloproliferative Disorders | Major topic |
| Reactive Oxygen Species | Major topic |
| Thrombosis | Major topic |
| Inflammation | Major topic |
| Janus Kinase 2 | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| Toll-Like Receptor 4 | |
| Philadelphia Chromosome | |
| Calgranulin B | |
| Adult |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12676820 | CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. | Circ Res | 2003 | https://conductscience.org/library/papers/12676820 | PubMed |
| 2 | 23033268 | Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). | Blood | 2012 | https://conductscience.org/library/papers/23033268 | PubMed |
| 3 | 16115126 | Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. | Br J Haematol | 2005 | https://conductscience.org/library/papers/16115126 | PubMed |
| 4 | 34527000 | The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. | Front Immunol | 2021 | https://conductscience.org/library/papers/34527000 | PubMed |
| 5 | 31648311 | Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera. | Blood Adv | 2019 | https://conductscience.org/library/papers/31648311 | PubMed |
| 6 | 12697438 | Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. | Trends Immunol | 2003 | https://conductscience.org/library/papers/12697438 | PubMed |
| 7 | 28428710 | CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28428710 | PubMed |
| 8 | 17105814 | Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. | Blood | 2007 | https://conductscience.org/library/papers/17105814 | PubMed |
| 9 | 18689872 | RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. | Carcinogenesis | 2008 | https://conductscience.org/library/papers/18689872 | PubMed |
| 10 | 12579287 | Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. | Oncol Rep | 2003 | https://conductscience.org/library/papers/12579287 | PubMed |
| 11 | 17359388 | Monocyte-derived dendritic cells from highly atopic individuals are not impaired in their pro-inflammatory response to toll-like receptor ligands. | Clin Exp Allergy | 2007 | https://conductscience.org/library/papers/17359388 | PubMed |
| 12 | 25037629 | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. | Blood | 2014 | https://conductscience.org/library/papers/25037629 | PubMed |
| 13 | 23071157 | Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. | Circ Res | 2013 | https://conductscience.org/library/papers/23071157 | PubMed |
| 14 | 23765228 | Toll-like receptor alterations in myelodysplastic syndrome. | Leukemia | 2013 | https://conductscience.org/library/papers/23765228 | PubMed |
| 15 | 23174192 | Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? | Leuk Res | 2013 | https://conductscience.org/library/papers/23174192 | PubMed |
| 16 | 26538833 | The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/26538833 | PubMed |
| 17 | 20655352 | Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. | Exp Hematol | 2010 | https://conductscience.org/library/papers/20655352 | PubMed |
| 18 | 33128580 | HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. | J Mol Med (Berl) | 2021 | https://conductscience.org/library/papers/33128580 | PubMed |
| 19 | 18809714 | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. | J Exp Med | 2008 | https://conductscience.org/library/papers/18809714 | PubMed |
| 20 | 24085768 | JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. | Blood | 2013 | https://conductscience.org/library/papers/24085768 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941857 | TLR2 Signaling in Myeloproliferative Neoplasms: Pathophysiological Roles, Mutation-Dependent Heterogeneity, and the Differential Efficacy of Ruxolitinib. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941857 | PubMed |
| 41436639 | Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms. | Leukemia | 2026 | https://conductscience.org/library/papers/41436639 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| S100A9 | 6280 | PubTator's text mining | https://conductscience.org/library/genes/6280 | NCBI Gene |
| TLR2 | 7097 | PubTator's text mining | https://conductscience.org/library/genes/7097 | NCBI Gene |
| TLR4 | 7099 | PubTator's text mining | https://conductscience.org/library/genes/7099 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39157201
GET https://conductscience.org/api/papers/v1/39157201/references?page=2